Brevican

A BRAIN-specific hyalectin that may play a role in terminally differentiating NEURONS. It is found highly overexpressed in primary BRAIN TUMORS and in experimental models of GLIOMA.

Also Known As:

Networked: 67 relevant articles (0 outcomes, 8 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Viapiano, Mariano S: 8 articles (04/2021 - 08/2003)
2.	Matthews, Russell T: 6 articles (01/2020 - 08/2003)
3.	Hockfield, S: 5 articles (10/2001 - 01/2000)
4.	Andreasson, Ulf: 4 articles (05/2021 - 09/2019)
5.	Blennow, Kaj: 4 articles (05/2021 - 09/2019)
6.	Minta, Karolina: 4 articles (05/2021 - 09/2019)
7.	Portelius, Erik: 4 articles (05/2021 - 09/2019)
8.	Zetterberg, Henrik: 4 articles (05/2021 - 09/2019)
9.	Brinkmalm, Gunnar: 3 articles (05/2021 - 01/2021)
10.	Jeppsson, Anna: 3 articles (05/2021 - 09/2019)

Related Diseases

1.	Glioma (Gliomas) 12/19/2012 - "Moreover, the role of brevican in the growth and progression of glioma was demonstrated by in vivo studies. " 12/19/2012 - "In this study, immunohistochemistry staining for brevican expression was performed in malignant gliomas and benign controls. " 12/19/2012 - "The aim of this study was to examine whether brevican is a predictor of glioma and its roles in glioma cell motility. " 09/01/2005 - "In the present study, we examined brevican-degrading activities of ADAMTS-1, -4 and -5 at the cellular level, and their expression and localization in human glioma tissues. " 01/01/2020 - "The Role of BEHAB/Brevican in the Tumor Microenvironment: Mediating Glioma Cell Invasion and Motility."
2.	Neoplasms (Cancer) 10/01/2001 - "These data suggest that up-regulation and proteolytic cleavage of BEHAB/brevican increase significantly the aggressiveness of glial tumors. " 10/01/2001 - "Histological examination showed that the BEHAB/brevican-transfected tumors were just as, if not more, aggressive than control tumors, even though the BEHAB/brevican tumors had been growing for only approximately two-thirds the time as long as control tumors. " 04/01/2001 - "Here, the authors present a review of the literature on glial tumor invasion by modulation of the ECM and propose a two-step model for BEHAB/brevican's role in this process." 04/01/2001 - "Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican." 12/19/2012 - "This study suggests that expression of brevican is associated with glioma cell adhesion, motility and tumor growth, and also is related to glioma cell differentiation, therefore it may be a marker for malignance degree of glioma."
3.	Brain Injuries (Brain Injury) 07/01/2000 - "In order to study a potential role of brevican in the glial reaction after brain injury, its expression was analysed following entorhinal cortex lesion in rats (12 h, 1, 2, 4, 10, 14 and 28 days and 6 months post lesion). " 05/01/2005 - "The effect of hypoxic-ischemic brain injury in perinatal rats on the abundance and proteolysis of brevican and NG2." 04/01/2001 - "BEHAB/brevican expression is also upregulated during periods of increased glial cell motility in development and following brain injury. " 01/01/2021 - "Altered levels of two extracellular matrix (ECM) proteoglycans, brevican and neurocan, have been found in brain injury models; however, their proteolytic processing in traumatic brain injury (TBI) remains unexplored. " 09/25/2019 - "Background Brevican, neurocan, tenascin-C and tenascin-R are extracellular matrix proteins present in brain that show increased expression in experimental animal models of brain injury. "
4.	Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer's disease, other types of dementia and non-demented controls: A cross-sectional study." 01/01/2021 - "The study aim was to quantify proteolytic peptides derived from brevican and neurocan in human CSF of patients with Alzheimer's disease (AD) and vascular dementia (VaD) compared with controls. " 01/01/2021 - "Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease."
5.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/01/2021 - "The study aim was to quantify proteolytic peptides derived from brevican and neurocan in human CSF of patients with Alzheimer's disease (AD) and vascular dementia (VaD) compared with controls. " 01/01/2021 - "Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease."

Related Drugs and Biologics

1.	Neurocan
2.	Aggrecans (Aggrecan)
3.	Class 5 Receptor-Like Protein Tyrosine Phosphatases
4.	Chondroitin Sulfate Proteoglycans
5.	Tenascin
6.	Messenger RNA (mRNA)
7.	Peptides (Polypeptides)
8.	Fibronectins (Fibronectin)
9.	Complementary DNA (cDNA)
10.	tenascin R

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Infusion Pumps (Infusion Pump)